New Data to Be Presented at the ISTH 2020 Virtual Congress Demonstrating Octapharma’s Commitment to Patients With Bleeding Disorders
13.7.2020 14:37:00 EEST | Business Wire | Press release
Octapharma announced today that new research findings from its haematology portfolio will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place on 12–14 July 2020.
The NuProtect study (NCT01712438) investigated the immunogenicity, efficacy and safety of Nuwiq® (simoctocog alfa) in 108 previously untreated patients with haemophilia A. The final results of the study showed a cumulative incidence of high-titre anti-FVIII inhibitors of 17.6%. Patients who completed the NuProtect study were offered participation in a long-term extension study (NCT01992549). The results of the extension study will be presented for the first time at ISTH 2020.
In patients who develop inhibitors, immune tolerance induction (ITI) with repeated FVIII administration is the only proven approach to eradicate inhibitors. Three posters will be presented at ISTH 2020 reporting on the success of ITI with two of Octapharma’s FVIII products, octanate® and Nuwiq®.
The titles of the posters are provided below. All abstracts are available on the ISTH website.
Poster PB0999 Long-term immunogenicity, efficacy and safety of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect PUP study
Poster PB1001 Immune tolerance induction (ITI) with a single factor VIII/von Willebrand factor concentrate in haemophilia A patients with inhibitors - Update from the ObsITI Study
Poster PB1044 Immune tolerance induction with octanate® in patients with haemophilia A and inhibitors: An ongoing case series from a Malaysian centre
Poster PB1047 Immune tolerance induction with simoctocog alfa in patients with haemophilia A: An ongoing multicentre case series from the UK
Octapharma will be sponsoring two scientific symposia at ISTH 2020 on haemophilia A and von Willebrand disease (VWD). The haemophilia A symposium will include new clinical and real-world data on Nuwiq®, including final results from the NuProtect study and its long-term extension as well as experience with personalized prophylaxis in previously treated patients. New studies of ITI and the relevance of FVIII in managing joint and bone health will also be discussed. The VWD symposium will address the challenges of diagnosing VWD and particular issues facing women with VWD, as well as discussing the use of wilate® for prophylaxis and during surgery.
Both symposia will be held on Tuesday 14 July (8:45 am EDT and 10:15 am EDT) on the ISTH virtual congress platform and will be freely available to all healthcare professionals. The symposia will remain on the congress platform for 90 days and be available on the ISTH Academy website for one year.
“We are very pleased to share the positive data across our product portfolio addressing the needs of individuals with haemophilia and von Willebrand disease”, said Dr Larisa Belyanskaya, Head of IBU Haematology at Octapharma. Olaf Walter, Board Member at Octapharma, added that “the data cover the large spectrum of care required by patients with coagulation disorders, and demonstrate Octapharma’s commitment to improving patients’ lives at an individual level.”
About Octapharma
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs more than 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Haematology, Immunotherapy, and Critical Care.
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, with a combined capacity of approximately 8 million litres of plasma per annum. In addition, Octapharma operates more than 140 plasma donation centres across Europe and the US. More information on www.octapharma.com
About Nuwiq®
Nuwiq® (simoctocog alfa) is a 4th generation recombinant factor VIII (rFVIII) protein, produced in a human cell line without chemical modification or fusion with any other protein1. It is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for von Willebrand factor1. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 previously treated patients (PTPs; 190 individuals) with severe haemophilia A, including 59 children1. Nuwiq® is available in 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU presentations2. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) across all age groups2.
- Lissitchkov T et al. Ther Adv Hematol 2019; doi: 10.1177/2040620719858471.
- Nuwiq® Summary of Product Characteristics.
About wilate®
wilate® is a high-purity human von Willebrand factor/factor VIII (VWF/FVIII) concentrate, that undergoes two virus inactivation steps during its production.1 No albumin is added as a stabiliser1. The purification processes result in a 1:1 ratio of VWF to FVIII that is similar to normal plasma1. wilate® contains a VWF triplet structure and content of large high molecular weight multimers similar to normal human plasma1. wilate® is exclusively derived from large pools of human plasma collected in approved plasma donation centres2. wilate® is available in 500 IU and 1000 IU presentations. wilate® is indicated for the prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) alone is ineffective or contra-indicated, and for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) 2.
- Stadler M et al. Biologicals 2006; 34:281-8.
- wilate® Summary of Product Characteristics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200713005330/en/
Contact information
Macarena Guillamon
corporatecommunications@octapharma.com
Phone: +41 055 451 21 21
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brightfin Unveils Budget Clarity AI, Giving Every Finance and IT Leader a Financial Analyst at the Tip of Their Fingers29.9.2026 17:18:00 EEST | Press release
Brightfin, the leader in technology financial management, today announced Budget Clarity AI, a new capability that gives finance and IT teams instant, self-service answers to the budget questions they field dozens of times a day. Built into the Brightfin platform, Budget Clarity AI acts as an always-available financial analyst, letting users ask plain-language questions about their spend and get grounded answers, visualizations, and recommendations in seconds. Finance and IT leaders are fielding an ever-growing volume of ad-hoc budget questions from stakeholders across the business, while the analysts who could answer them are stretched thin. Budget Clarity AI is designed to close that gap. Users don't need to know ServiceNow, and they don't need to know Brightfin's products — they only need to know what they're trying to get done, and the tool routes them to the answer in one click. What Budget Clarity AI Delivers A simplified experience: users don't need to know ServiceNow or Brightf
Laserfiche Names Garrett Boss as CIO to Lead Enterprise IT, Security, and Business Transformation29.9.2026 17:00:00 EEST | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — today announced the appointment of Garrett Boss as chief information officer. Boss will oversee Laserfiche’s global IT services team and business transformation office, including deployment of internal Laserfiche solutions and all other enterprise-wide IT systems. In this role, he will also oversee governance, risk, and compliance, supporting Laserfiche's mission to scale AI innovation while safeguarding the critical content and lifecycle tools customers rely on. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929335686/en/ Garrett Boss joins Laserfiche as chief information officer. “Laserfiche’s own technology infrastructure and security posture are central to how we deliver an exceptional product and responsive services,” said CEO Karl Chan. “Garrett is a proven leader with a track record of leading global IT and go
Andersen Global Strengthens Argentina Presence with Fidem Partners29.9.2026 16:30:00 EEST | Press release
Andersen Global expands its tax and transaction capabilities in Argentina through a Collaboration Agreement with Fidem Partners, strengthening its presence and service offerings in the market. Established in 2011, Fidem Partners advises businesses on tax and compliance, M&A, and business process outsourcing. The firm serves companies across the energy, technology, financial services, agribusiness, and consumer goods sectors with deep experience serving subsidiaries of multinational companies in Argentina. Its multidisciplinary team draws on experience from leading professional services firms and business environments to provide practical guidance throughout the key stages of the business lifecycle. "Most of our work is with subsidiaries of multinational companies operating in Argentina, where the regulatory environment demands judgment, not just compliance," said Darío H. Díaz, managing partner of Fidem Partners. "Collaborating with Andersen Global gives our clients access to a global
CEO Pay Tops $18 Million as Turnover Drives Six-Year High in Sign-On Bonuses, According to Diligent29.9.2026 16:00:00 EEST | Press release
Median granted CEO pay at S&P 500 companies rose by more than 8% in 2025 to reach $18.2 million, while cash sign-on bonuses for incoming CEOs hit a six-year high, according to the Executive Compensation in 2026 report from Diligent Market Intelligence. The findings point to a more consequential compensation environment for boards: leadership talent is in shorter supply, CEO transitions are costly, and investors continue to scrutinize how pay decisions connect to performance and long-term value. The Russell 3000 also saw remuneration packages grow larger, with median granted CEO pay climbing over 2% to $7.4 million. “This level of growth has been fueled by performance-based equity and stock awards while both indices have been delivering strong total shareholder returns,” said Josh Black, Editor-in-Chief of Diligent Market Intelligence. “Boards are also increasingly viewing CEOs as a scarce global talent pool.” CEO turnover drives higher transition costs Cash sign-on bonuses for new S&P
Momentum Grows for Miro MCP as Users Embrace the Canvas for AI Collaboration29.9.2026 16:00:00 EEST | Press release
Miro®, the collaboration and context layer for the AI era, has reported more than 16 million calls to its MCP server since its launch in February 2026, with usage more than doubling since May. In September alone, MCP calls are on track to reach 6 million*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929837812/en/ Miro's MCP server is a Model Context Protocol integration letting AI tools connect to Miro boards—creating diagrams, tables, and canvas content, and reading existing board data programmatically. Teams increasingly rely on AI to accelerate work—from discovery and planning to design and code. Yet most AI interactions happen in chat windows or static outputs that exist separately from the team's actual workspace. Miro's MCP server changes this by giving users a way to make the output from their AI tools visual, immediately editable, and accessible to the whole team on a shared canvas. Miro user data shows Claude
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom